Table 1 Demographics, clinical course and treatment in cases with Burkholderia contaminans endophthalmitis
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
|---|---|---|---|---|---|---|
Sex / age (years) | Male / 73 | Male / 89 | Male / 74 | Male / 86 | Female / 59 | Male / 72 |
Date of surgery | 13.01.19 | 14.01.19 | 13.01.19 | 13.01.19 | 13.01.19 | 08.01.19 |
Eye(s) operated | Left | Both | Both | Left | Both | Both |
Eye with endophthalmitis | Left | Left | Left | Left | Right | Left |
Date of diagnosis | 26.01.19 | 26.01.19 | 28.01.19 | 29.01.19 | 18.02.19 | 30.04.19 |
Time to diagnosis (days) | 13 | 12 | 15 | 16 | 36 | 112 |
Time to recurrence (days) | 13 18 71 | 16 | 13 16 | 27 | – | 32 43 |
Number of recurrences | 3 | 1 | 2 | 1 | 0 | 2 |
Intravitreal antibiotics (n) | Vancomycin (1) Ceftazidime (7) Piperacillin /tazobactam (8) Gentamicin (4) | Vancomycin (1) Ceftazidime (7) Piperacillin/ tazobactam (3) Gentamicin (4) | Ceftazidime (5) Gentamicin (5) | Ceftazidime (2) Piperacillin/ tazobactam (3) Gentamicin (2) | Ceftazidime (3) Piperacillin/ tazobactam (4) Gentamicin (3) | Vancomycin (3) Ceftazidime (3) Piperacillin/ tazobactam (2) |
Systemic antibiotics | Ciprofloxacin 750 mg × 2 | Ciprofloxacin 500 mg × 2 | Ciprofloxacin 750 mg × 2 | Ciprofloxacin 250 mg × 2 | Ciprofloxacin 500 mg × 2 | – |
Date of IOL/ lens capsule removal | 26.02.19 /27.05.19 | 28.02.19 | – | 01.03.19 | 05.03.19 | 18.07.19 |
Number of treatments | 15 | 10 | 5 | 5 | 7 | 5 |
Date of secondary IOL surgery | 28.10.19 | 21.08.19 | – | 14.10.19 | 17.06.20 | 21.10.19 |
Time to secondary IOL (days) | 288 | 219 | – | 274 | 521 | 286 |
Final CDVA | 1.2 | 0.9 | 1.0 | 1.0 | 0.8 | 0.8 |